Authors

Xuan Qi, Yu Tian, Chao Sun, Hongtao Jin, Meng Ding, Yuxiang Han, Huifang Guo#

Departments

Department of Rheumatism and Immunology, The Second Hospital of Hebei Medical University, Shijiazhuang, PR China

Abstract

Objective: To analyze the correlation of serum IL-35 level with ESSDAI, IL-17 and laboratory biochemical indexes in primary Sjogren's syndrome (PSS). 

Methods: Our observation group contained 40 patients with PSS admitted to the rheumatic immunology Department of our hospital from July 2017 to June 2019, and 40 healthy people served as a control group. IL-35 and IL-17 levels were detected by enzyme-linked immunosorbent assay and the ESSDAI standard proposed by Seror. The difference of clinical data between the two groups was analyzed, and the relationship between IL-35 level and ESSDAI disease activity, IL-17, and laboratory biochemical indicators [including erythrocyte sedimentation rate (ESR), neutrophil/lymphocyte ratio (NLR), globulin (GLB), C-reactive protein (CRP), and platelet (PLT)] was explored. 

Results: The serum IL-35 level in the observation group was significantly lower than that in the healthy control group (P<0.05), and the serum IL-17 level in the observation group was significantly higher than that in the healthy control group (P<0.05). The serum IL-35 level in the observation group was negatively correlated with ESSDAI, age, IL-17, ESR, NLR, Glb, CRP, and PLT (P<0.01). 

Conclusion: IL-35 can be used as an indicator of disease activity. IL-35 and IL-17 participate in the pathogenesis of Sjogren's syndrome and provide new therapeutic avenues for patients.

Keywords

PSS, IL-35, ESSDAI, IL-17.

DOI:

10.19193/0393-6384_2020_3_240